论文信息 - Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. - 字舞流文

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.

J. Blay | A. Italiano | N. Sevenet | O. Trédan | N. Dohollou | M. Kind | E. Barouk-Simonet | M. Longy | T. Grellety | F. Peyraud

[1] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[2] M. Tanemoto. Diagnostic Use of Base Excess in Acid-Base Disorders. , 2018, The New England journal of medicine.

[3] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[4] A. Jakubowska,et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. , 2015, The Lancet. Oncology.

[5] Junjie Chen,et al. PALB2 Regulates Recombinational Repair through Chromatin Association and Oligomerization* , 2009, The Journal of Biological Chemistry.